A unique cardiopoietic platform to be discovered at Mayo Clinic (USA).
Fundamental research is being conducted at Mayo Clinic (Rochester, Minnesota, USA) to unveil the mechanisms that make a stem cell differentiate into a heart cell. Prof. André Terzic Dr. Atta Behfar head the research.
How to translate academic excellence into an innovative industrial project?
Cardio3 SA, the Company’s predecessor entity, was created by Michel Lussier, Christian Homsy, William Wijns and Jozef Bartunek to leverage research collaboration between Mayo Clinic and Cardiovascular Center Aalst in Belgium
The Regenerative Medicine Era:
Positioning the Company as a global leader in cell therapy for ischemic heart failure.
Cardio3 SA becomes Cardio3 BioSciences SA and licenses the cardiac stem cell technology developed by Mayo Clinic to further develop C-Cure®.
First patient treated with C-Cure®
The beginning of clinical testing of the Cardiopoiesis technology in human.
A first patient is being treated with C-Cure® in the Phase II clinical trial.
Encouraging Phase II results
A great clinical milestone for a unique git cell therapy with CHART-1 in Europe.
Publication of the Phase II results for C-Cure® - significan`t functional and clinical benefits are demonstrated.
C-Cure®: one step ahead
The most advanced cell therapy for ischemic heart failure worldwide.
- Cardio3 BioSciences, as the Company was previously known as, completes European IPO and is quoted on Euronext Brussels and Paris under the ticker CARD.
C-Cure® in the U.S.
Preparation of a Phase III trial in the U.S. with CHART-2
Time for diversification
Celyad enters the immuno-oncology area with the NKR-T technology.
- First US Patent 9.181.527 relating to allogeneic human primary T-cells that are engineered to be TCR deficient and express a CAR.
- Dosing of the last patient of CHART-1, European Phase III trial in cardiology.
- IPO on Nasdaq (USD 100 million gross proceeds)
Celyad becomes an international company with leading programs in immuno-oncology.
- CHART-1 Phase I 9-month clinical data of CHART-1 Phase III trial were published in the European Heart Journal (click here to download the publication).
- Celyad presented the primary clinical data of CHART-1 Phase III trial at the European Society of Cardiology.
- Signature of an exclusive license agreement with the Japanese company ONO PHARMCEUTICAL CO., LTD, one of the global leaders in the immuno-oncology field, for the development and commercialization of Celyad’s allogeneic NKR-2 T-cell immunotherapy in Japan, Korea and Taiwan.
- Strategic collaboration with Institut Curie (France) to develop NKR-T immuno-oncology program.
- First US patent covering a method of producing allogeneic TCR-deficient CAR-T cells
Celyad, the next generation CAR-T company
Opening new avenues for the treatment of both hematological and solid tumors with the THINK trial
- Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents
- Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells
- Celyad obtains FDA approval to initiate the CYAD-01 CAR-T cells THINK trial in the USA
- USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells
- Celyad issues a White Paper about CYAD-01 current knowledge and differences with classical CAR-T technologies
- Initiation of the THINK (Therapeutic Immunotherapy with NKG2D) trial in Belgium with registration of a first colorectal cancer patient.
- Celyad Announces USPTO Decision to Uphold US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells